RHHVF Articles, Roche Holding Div Rts

Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries. The administrators signed a definitive ...

Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted a...

Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted a...

Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 INAVO120 study of the investigational therapy, inavolisib, in combinati...

Roche Holding AG (OTC: RHHBY) has agreed to acquire a privately held obesity company Carmot Therapeutics, seeking to challenge ...

Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene m...

Roche Holdings AG's (OTC: RHHBY) nine months sales increased by 1% (down 6% in CHF) to CHF 44.1 billion, even though the co...

Monte Rosa Therapeutics Inc (NASDAQ: GLUE) entered into a strategic collaboration and licensing agreement with Roche Holdings AG (OT...

Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic too...

Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY) for two undisclosed early-sta...